Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Saroglitazar in NAFLD with PCOS
NCT03617263Phase 2Terminated
- Sponsor
- Zydus Therapeutics
- Start
- Feb 2019
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in non-alcoholic fatty liver disease (NAFLD) comparing Saroglitazar Magnesium 4 mg with Placebo (2 arms). Primary endpoint: Change in Hepatic Fat Content from Baseline at 24 weeks. Started Feb 2019; status: terminated.
02
Drugs
saroglitazar magnesium
03
Conditions
non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT03617263.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03617263.